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Abstract
With the introduction of an organized mammographic screening, the incidence of ductal carcinoma in situ (DCIS) has experienced an
important increase. Our experience with sentinel lymph node biopsy (SLNB) among patients with DCIS is reviewed.
We collected retrospective data on patients operated on their breasts for DCIS (pTis), DCIS with microinvasion (DCISM)
(pT1mi) and invasive ductal carcinoma (IDC) sized 2cm (pT1) between January 2002 and June 2016, focusing on the result of
SLNB.
543 DCIS, 84 DCISM, and 2111 IDC were included. In cases of DCIS and DCISM, SLNB resulted micrometastatic
respectively in 1.7% and 6.0% of cases and macrometastatic respectively in 0.9% and 3.6% of cases. 5-year disease-free
survival and overall survival in DCISM and IDC were similar, while significantly longer in DCIS. 5-year local recurrence
rate of DCIS and DCISM were respectively 2.5% and 7.9%, and their 5-year distant recurrence rate respectively 0% and 4%.
IDC, tumor grading ≥2 and lymph node (LN) macrometastasis were significant predictors for decreased overall survival.
Significant predictors for distant metastases were DCISM, IDC, macroscopic nodal metastasis, and tumor grading ≥2.
Predictors for the microinvasive component in DCIS were tumor multifocality/multicentricity, grading ≥2, ITCs and
micrometastases.
Our study suggests that despite its rarity, sentinel node metastasis may also occur in case of DCIS, which in most cases are
micrometastases. Even in the absence of an evident invasive component, microinvasion should always be suspected in these cases,
and their management should be the same as for IDC.
Abbreviations: CI = confidence interval, DCIS = ductal carcinoma in situ, DCISM = ductal carcinoma in situ with microinvasion,
DFS= disease-free survival, ER = estrogen receptor, IDC = invasive ductal carcinoma, LN= lymph node, OS = overall survival, PR =
progesteron receptor, PVI= peritumoral vascular invasion, SLNB= sentinel lymph node biopsy, TNM= tumor, noes, andmetastasis.
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1Key Points
What is this paper adds: ductal carcinoma in situ wit
microinvasion presented disease free survival and overa
survival similar to invasive ductal carcinoma;
Ductal carcinoma in situ with microinvasion presented diseas
free survival and overall survival shorter than ducta
carcinoma in situ;
Ductal carcinoma in situwithmicroinvasion had shorter disease
free survival mainly because distant metastases occurrence;
Lymph node status could predict tumor microinvasion;
Isolated tumor cells could have a role in tumor microinvasio
prediction.h
ll
e
l
-
n
1. Introduction
Although usually in situ cancer should not be able to shed
neoplastic cells into the bloodstream or infiltrate the lymphatic
net, there is a variable reported percentage of ductal carcinoma in
Bertozzi et al. Medicine (2019) 98:1 Medicinesitu (DCIS) which present an axillary nodal involvement, with
higher rates noted in the premammographic era.[1–6] Nodal
involvement in DCIS likely depends on the misdetection of occult
microscopic invasive foci (occult microinvasion) due to technical
limitations in specimen pathological assessment.[1–6] Micro-
invasion is defined as the extension of cancer cells beyond the
basal membrane into the adjacent tissues, sized 1mm,[7] but a
recent study hypothesized that tumor cell dissemination may also
occur before stroma invasion.[8] Some authors have described a
prevalence of even 58.3% of occult invasion by histological re-
examination of specimens of patients affected by DCIS with
nodal metastasis, and thus significantly higher than that of
specimens of pTisN0 patients.[9] However, microinvasive foci are
shown to be very difficult to detect especially in the case of very
wide intraductal carcinoma.[10,11]
Considering the controversy around pathogenesis and man-
agement of axillary metastases in DCIS, we reviewed our
experience with sentinel lymph node biopsy (SLNB) among
patients with DCIS. In particular, in this study, we evaluated the
prevalence of sentinel node metastasis and their clinical role by
SLNB performed in women affected by DCIS, as well as their
influence on patient outcome in terms of overall survival (OS) and
disease-free survival (DFS).2. Materials and methods
For this chart review study, we collected retrospective data
about all consecutive women operated on their breast for DCIS
or invasive ductal carcinoma (IDC) sized 2cm (pT1) in our
Department between January 2002 and June 2016. The study
was designed according to the dictates of the general
authorization to process personal data for scientific research
purposes by the Italian Data Protection Authority. We excluded
all histotypes other than ductal carcinoma, male breast cancer,
and tumors sized >2cm by radiological diagnosis or micro-
scopical evaluation.
Collected data included patient characteristics (age at diagno-
sis, body mass index [BMI], positive family history for breast or
ovarian cancer, fertility status, eventual use of estroprogestinic
therapies), tumor characteristics (histotype, grading, expression
of estrogen receptor (ER), progesterone receptor (PR), HER2/neu
expression, and Mib1/Ki-67, multifocality/multicentricity, peri-
tumoral vascular invasion (PVI), peritumoral inflammation,
nodal extracapsular invasion or bunched axillary nodes ),[12]
surgical and non surgical management.
European guidelines were followed to routinely assess the
pathological specimens.[13,14] The samples with a maximum
diameter of 30mm or less were completely sliced and examined,
while for larger specimens, the sampling method followed the
European guidelines.[13,14] The World Health Organization
criteria were used to classify tumor histology[15] and nodal
status (tumor, noes, and metastasis [TNM] classification VII ed.
American Joint Cancer Committee/Union Internationale Contre
le Cancer [AJCC/UICC], 2009), and the recommendations of
AFIP (DCIS) and Elston Ellis (IDC) were used to evaluate tumor
grade.[16,17] Peritumoral inflammation, PVI, multifocality/multi-
centricity, and nodal status were defined as previously
described.[18,19] PR, ER, Ki-67/Mib-1, andHer-2/Neu expression
were evaluated by immunohistochemistry. The authors consid-
ered PR or ER receptor positivity as positive in any nuclear
staining ≥1%. In addition, Her-2/Neu was considered overex-
pressed when staining 3+ or 2+ with FISH amplification, negative
if value was 0, 1+ or 2+ without FISH amplification.2As previously stated, considered molecular subtypes of breast
cancer were luminal A, luminal B, luminal Her, Her2-enriched,
and basal-like.[18]
The study population was divided into 3 groups, by the ductal
in situ component and the ductal invasive component: DCIS
(pTis), ductal carcinoma in situ with microinvasion (DCISM)
(pT1mi), and IDC sized 2cm (pT1). Data were analyzed
using R (version 3.2.3; R Core Team (2016); R: A language
and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria; URL https://www.
R-project.org/) and considering as significant P<.05. Univariate
analysis was performed by t test in cases of continuous variables,
chi-square test or Fisher exact test in cases of categorical
variables. We also performed univariate and multivariate
survival analyses by Kaplan-Meier curves, Log-rank test, and
Cox proportional hazards regression models. OS and DFS were
considered to be the main outcomes, and were compared among
the 3 groups drawing Kaplan–Meier curves. Moreover, DFS was
considered separately for loco-regional and distant recurrences.
Univariate and multivariate Cox proportional hazards regres-
sion analysis was performed. In multivariate models included
were all factors with less than 20%missing values and that had a
P value<.200 in univariate analysis. In addition, in the
multivariate model all selected factors and their interactions
were accommodated in a single analysis, except when the
interaction term was non-significant (in which case we analyzed
the no-interaction model). Then a stepwise selection was
performed to obtain the final multivariate regression model.
For the variables with a P value<.200 and missing values
between 20% to 40% of the total subjects a second multivariate
Cox proportional hazards regression analysis was performed
with random imputation of missing values and with a subsequent
stepwise selection to obtain the final multivariate regression
model. Univariate and multivariate logistic regression analyses
were also performed.
In the multivariate logistic regression model considering only
DCIS and DCISM, the following were considered as the
dependent variable: DCISM, the presence of nodal metastases,
and the presence of ITCs. The possible predictive factors (for
DCISM or nodal involvement among DCIS) were considered as
independent variables. In the multivariate model, all potentially
influencing factors and their interactions were accommodated in
a single analysis, except when the interaction term was non-
significant (in which case we analyzed the no-interaction model).
Furthermore, we included in the initial multivariate model all
the factors with less than 20% missing values, that had a
P value<.200 in univariate analysis and then we performed a
stepwise selection to obtain the final multivariate logistic
regression model. For variables with a P value<.200 and missing
values between 20% and 40% of the total subjects, a second
multivariate logistic regression analysis was performed with
random imputation of missing values. Benjamini and Hochberg
correction was applied to all multivariate analysis.[20]3. Results
3.1. Patient characteristics and treatment
Among 7798 breast cancers operated on in our clinic, 543 DCIS,
84 DCISM, and 2111 IDC pT1 were found. Table 1 shows the
population characteristics among the 3 studied groups. Women
affected by IDC presented older age than the other groups and
breast tumors were more frequently discovered by clinical
Table 1
Population characteristics and treatment description. The reported values aremeans (± standard deviation) or percentages (and absolute
values: cases/total available data excluding the unknown). Where appropriate p-values refers to t-test, chi-square test or Fisher exact
test.
DCIS (543) DCISM (84) IDC (2111) P (
∗
)
Patient characteristics
Woman age at surgery, years 58.79 (±11.36) 58.80 (±11.70) 60.56 (±12.27) 2
BMI, Kg/m2 25.86 (±5.22) 25.34 (±4.01) 25.59 (±4.74) NS
Tobacco smoke 8.7% (31/358) 4.6% (3/65) 8.9% (137/1543) NS
Familial history of cancer 42.0% (66/157) 44.4% (8/18) 36.4% (187/514) NS
Use of estrogen/progesteron pills 33.0% (36/109) 14.3% (2/14) 29.4% (91/310) NS
Post-menopausal status 77.7% (422/543) 76.2% (64/84) 80.6% (1698/2107) NS
Clinical suspicion of a palpable lesion 13.9% (59/424) 13.0% (10/77) 26.4% (424/1605) 2,3
Treatment characteristics
Definitive breast surgery
Conservative 58.7% (319/543) 35.7% (30/84) 67.0% (1414/2111) 1,2,3
Mastectomy 41.3% (224/543) 64.3% (54/84) 33.0% (697/2111) 1,2,3
Definitive axilla surgery
SLNB 97.8% (531/543) 69.0% (58/84) 62.8% (1326/2111) 1,2
CALND 2.2% (12/543) 31.0% (26/84) 37.2% (785/2111) 1,2
Non surgical therapy
Adjuvant radiotherapy 51.9% (255/491) 35.4% (29/82) 66.4% (1272/1917) 1,2,3
Adjuvant chemotherapy 5.1% (25/486) 13.4% (11/82) 35.4% (675/1906) 1,2,3
Adjuvant hormonal therapy 51.8% (253/488) 62.2% (51/82) 83.7% (1601/1913) 2,3
DCIS=ductal carcinoma in situ, DCISM=DCIS with microinvasion, IDC= invasive ductal carcinoma, SLNB= sentinel lymph node biopsy, CALND= complete axilla lymph node dissection, BMI=body mass index.
∗
Significant differences with a P value<.05 between the following groups= (1) DCIS versus DCIS microinvasion, (2) DCIS vs IDC, (3) DCIS microinvasion versus IDC. NS=non-significant differences.
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tion (CALND) and adjuvant treatments were more commonly
performed in the IDC group (Table 1).3.2. Tumor characteristics and staging
Tumor and axilla characteristics are shown in Tables 2 and 3.
Comedo-like necrosis was more frequent in DCISM than in DCIS
or IDC and it was more frequent in DCIS than IDC (P<.05)Table 2
Tumor and axilla characteristics. The reported values are percentag
unknown). Where appropriate P values refers to chi-square test or F
DCIS (543)
Tumor characteristics
Molecular Subtype
Luminal A 54.5% (12/22)
Luminal B 13.6% (3/22)
Luminal Her 4.5% (1/22)
Her enriched 18.2% (4/22)
Basal-like 9.1% (2/22)
Ki-67/Mib-1 >20 25.5% (13/51)
Comedo-like necrosis 27.4% (149/543)
Multifocality/multicentricity 14.5% (79/543)
PVI 0.6% (3/543)
Peritumoral inflammation 0.0% (0/543)
Lymph nodes characteristics
Non axillary loco-regional lymph nodes 1.0% (5/516)
Isolated tumor cells 0.6% (3/543)
Micrometastases 1.7% (9/543)
Macrometastases 0.9% (5/543)
Extracapsular invasion of lymph node metastasis 0.0% (0/543)
Bunched axillary lymph nodes 0.0% (0/543)
DCIS=ductal carcinoma in situ, DCISM=DCIS with microinvasion, IDC= invasive ductal carcinoma, PV
∗
Significant differences with a P value<.05 between the following groups= (1) DCIS versus DCIS micr
3(Table 2). Multifocality/multicentricity was more common in
DCISM than in the other 2 groups (P<.05) (Table 2). In cases of
DCIS with or without microinvasion, SLNB resulted micro-
metastatic respectively in 6.0% and 1.7% of cases, and
macrometastatic respectively in 3.6% and 0.9% of cases
(Table 2). Table 3 shows the tumor staging characteristics. LN
status in DCIS has entailed a TNMstage II in 0.9%of cases, while
in cases of DCISM the nodal status has entailed a TNM stage II in
1.2% of cases and III in 2.4% of cases (Table 3).es (and absolute values: cases/total available data excluding the
isher exact test.
DCISM (84) IDC (2111) P (
∗
)
27.6% (8/29) 48.3% (821/1700) 3
34.5% (10/29) 30.9% (525/1700) NS
10.3% (3/29) 6.9% (118/1700) NS
13.8% (4/29) 4.6% (78/1700) 2,3
13.8% (4/29) 9.3% (158/1700) NS
40.6% (13/32) 31.9% (532/1669) NS
44.0% (37/84) 8.3% (175/2111) 1,2,3
45.2% (38/84) 15.4% (326/2111) 1,3
4.8% (4/84) 12.8% (270/2111) 1,2,3
1.2% (1/84) 2.1% (44/2111) 1,2
2.4% (2/83) 1.7% (33/1992) NS
3.6% (3/84) 2.3% (49/2111) 1,2
6.0% (5/84) 6.7% (142/2111) 1,2
3.6% (3/84) 20.4% (431/2111) 1,2,3
0.0% (0/84) 3.7% (79/2111) 2
2.4% (2/84) 0.7% (15/2111) 1,2
I=peritumoral vascular invasion.
oinvasion, (2) DCIS versus IDC, (3) DCIS microinvasion versus IDC. NS=non-significant differences.
Table 3
Tumor staging. The reported values are percentages (and absolute values=cases/total available data excluding the unknown). Where
appropriate P values refers to chi-square test or Fisher exact test.
DCIS (543) DCISM (84) IDC (2111) P (
∗
)
Nodal status
N0 97.4% (529/543) 90.5% (76/84) 72.7% (1535/2111) 1,2,3
N1 2.6% (14/543) 7.1% (6/84) 22.9% (483/2111) 1,2,3
N2–3 0.0% (0/543) 2.4% (2/84) 4.4% (93/2111) 1,2
TNM stage
I 99.1% (538/543) 96.4% (81/84) 81.2% (1714/2111) 1,2,3
II 0.9% (5/543) 1.2% (1/84) 14.5% (307/2111) 2,3
III 0.0% (0/543) 2.4% (2/84) 4.3% (90/2111) 1,2
Tumor grading
G 1 18.2% (99/543) 6.0% (5/84) 20.3% (429/2111) 1,3
G 2 48.8% (265/543) 53.6% (45/84) 58.3% (1230/2111) 2
G 3 33.0% (179/543) 40.5% (34/84) 21.4% (452/2111) 2,3
DCIS=ductal carcinoma in situ, DCISM=DCIS with microinvasion, IDC= invasive ductal carcinoma.
∗
Significant differences with a P value<.05 between the following groups= (1) DCIS versus DCIS microinvasion, (2) DCIS versus IDC, (3) DCIS microinvasion versus IDC. NS=non-significant differences.
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Figure 1 shows the Kaplan–Meier analysis. DCIS had better OS
and DFS than IDC and DCISM (P<.05) (Fig. 1 A and B). As
shown in Figure 1C and D the most significant difference (DCIS
had better DFS than IDC and DCISM) was observed among DFSFigure 1. Kaplan–Meier analysis. Panel (A) overall survival in the 3 analyzed grou
DCISM (P<.05) and DCIS versus IDC (P<.05). Panel (B) disease free survival in the
DCIS versus DCISM (P<.05) and DCIS versus IDC (P<.05). Panel (C) disease free s
rank test the following differences were significant: DCIS versus DCISM (P<.05) and
regional recurrences (breast and axilla) in the 3 analyzed groups. At the log-rank
DCIS=ductal carcinoma in situ, DCISM=DCIS with microinvasion.
4considering distant metastases. Furthermore, 5-year OS of
patients affected by DCIS with and without any microinvasive
component resulted respectively 98.8% (95% [confidence
interval] CI 96.4%–100.0%) and 99.8% (95%CI 99.4%–
100.0%), while for IDC was 98.3% (95%CI 97.7%–98.9%).ps. At the log-rank test the following differences were significant: DCIS verses
3 analyzed groups. At the log-rank test the following differences were significant:
urvival considering only distant metastasis in the 3 analyzed groups. At the log-
DCIS versus IDC (P<.05). Panel (D) disease free survival considering only loco-
test the following differences were significant: DCIS versus DCISM (P= .070).
Table 4
Univariate and multivariate Cox proportional hazards regression analysis. The results are reported as hazard ratio (HR) with 95%
confidence interval (CI).
HR (95% CI) P HR (95% CI) (x) P P (∗) HR (95% CI) (∗∗) P P (∗)
A) Overall survival
Study groups
DCIS Reference Reference Reference
DCISM 11.49 (1.04–126.79) <.05 9.96 (0.9–109.91) .061 .076 7.69 (0.69–85.98) .098 .109
IDC 10.52 (1.45–76.51) <.05 8.02 (1.08–59.71) <.05 .070 7.68 (1.03–57.09) <.05 .070
Woman age, years 1 (0.98–1.03) .802
BMI, Kg/m2 0.93 (0.84–1.02) .113
Tobacco smoke 0.41 (0.06–3.05) .388
Familial history of cancer 0.55 (0.11–2.73) .465
Estrogen/progesteron use 1.61 (0.27–9.61) .604
Post-menopausal status 1.1 (0.51–2.36) .815
Clinical suspicion of a palpable lesion 4.3 (2.24–8.24) <.05
Basal-like subtype 4.47 (2.2–9.08) <.05 3.1 (1.56–6.17) <.05 <.05
Ki-67/Mib-1>20 2.39 (1.12–5.09) <.05
Comedo-like necrosis 0.65 (0.23–1.82) .412
Multi-focality/-centricity 1.88 (0.97–3.67) .063 1.75 (0.88–3.47) .109 .109
PVI 1.42 (0.56–3.62) .460
Peritumoral inflammation 5.46 (1.95–15.31) <.05 2.44 (0.84–7.06) .100 .100
Tumor grading ≥2 2.45 (1.5–4) <.05 2.32 (1.39–3.87) <.05 <.05 1.98 (1.18–3.33) <.05 <.05
LN micrometastases 1.45 (0.45–4.69) .534
LN macrometastases 4.26 (2.33–7.77) <.05 2.92 (1.56–5.44) <.05 <.05 2.99 (1.61–5.55) <.05 <.05
B) Disease-free survival
Study groups
DCIS
DCISM 3.7 (1.53–8.93) <.05 3.12 (1.29–7.55) <.05 <.05 2.84 (1.17–6.9) <.05 <.05
IDC 2.1 (1.18–3.74) <.05 2.43 (1.31–4.48) <.05 <.05 2.28 (1.25–4.16) <.05 <.05
Woman age, years 0.99 (0.98–1.01) .273
BMI, Kg/m2 1 (0.96–1.04) .953
Tobacco smoke 0.38 (0.12–1.2) .100
Familial history of cancer 1.01 (0.46–2.22) .989
Estrogen/progesteron use 1.9 (0.71–5.1) .203
Post-menopausal status 0.86 (0.56–1.31) .475
Clinical suspicion of a palpable lesion 2.57 (1.74–3.8) <.05 1.64 (1.13–2.38) <.05 <.05
Basal-like subtype 4.34 (2.82–6.68) <.05 2.28 (1.5–3.48) <.05 <.05
Ki-67/Mib-1>20 2.85 (1.9–4.28) <.05 1.38 (0.95–2.01) .089 .089
Comedo-like necrosis 1.72 (1.11–2.65) <.05 1.43 (0.89–2.31) .138 .138 1.52 (0.94–2.46) .086 .089
Multi-focality/-centricity 1.52 (1–2.3) <.05
Lymphovascular invasion 0.93 (0.49–1.77) .823
Peritumoral inflammation 3.32 (1.55–7.12) <.05 1.88 (0.86–4.09) .113 .135
Tumor grading ≥2 2.56 (1.91–3.42) <.05 2.44 (1.8–3.32) <.05 <.05 1.97 (1.44–2.71) <.05 <.05
LN micrometastases 0.95 (0.42–2.16) .907
LN macrometastases 1.82 (1.21–2.74) <.05 1.41 (0.92–2.16) .111 .135
DCIS=ductal carcinoma in situ, DCISM=DCIS with microinvasion, IDC= invasive ductal carcinoma, LN= lymph nodes, BMI=body mass index, PVI=peritumoral vascular invasion.
(x) Multivariate model (excluded variables with>20% of NA values), (∗) Benjamini and Hochberg correction, (∗∗) multivariate model with random imputation of missing values (imputed if NA values 40% of all
cases). A) Overall survival. B) Disease free survival.
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respectively 2.5% and 7.9%, and their 5-year distant recurrence
rate respectively 0% and 4%.
In Table 4A the predictive factors for OS in our population
were tested. In multivariate analysis, we found as significant
predictive factors: IDC, tumor grading ≥2, and LN macro-
metastases. Furthermore, the most predictive multivariate model
had predictive support from the following included factors:
DCISM and peritumoral inflammation. In addition, considering
the multivariate model with imputation of the missing values,
also basal-like subtype (that was available only in a minority of
DCIS or DCISM for missing data) and multifocality/multi-
centricity were found to be predictive.
In Table 4B the predictive factors for DFS were assessed. The
following factors were found to be significant predictors for5reduced DFS: DCISM, IDC, and tumor grading≥2. Other factors
found to be predictive in the multivariate model were comedo-
like necrosis and peritumoral inflammation. Moreover, after
random imputation of the missing values, the following were also
found to be predictive factors for DFS: clinical suspicion of a
palpable lesion, basal-like subtype, and Mib1 >20%. Supple-
mental Tables 1 and 2, http://links.lww.com/MD/C726 show
that DCISM and IDC were associated with a reduced DFS in
comparison to DCISmainly due to distant metastases occurrence.
In the initial models for prediction of OS and DFS (Table 4 A, 4B,
Supplemental Table 1, and 2, http://links.lww.com/MD/C726),
we considered the basal information, and not the treatment
information such as radiotherapy or chemotherapy, because
treatment was standard among the considered patients. Howev-
er, findings did not change by implementing the models with
Table 5
Predictive factors for local tumor micronivasion among the 627 cases of DCIS or DCIS with micronivasion. Univariate and multivariate
logistic regression analysis.
OR (IC95%) P OR (CI 95%) (x) P P (
∗
)
Woman age (years) 1.00 (0.98–1.02) .971
BMI (Kg/m2) 0.97 (0.92–1.03) .279
Tobacco smoke 0.52 (0.15–1.75) .290
Familial history of cancer 1.1 (0.41–2.95) .845
Estrogen/progesteron use 0.34 (0.07–1.59) .170
Post-menopausal status 0.95 (0.55–1.65) .857
Clinical suspicion of a palpable lesion 0.84 (0.4–1.78) .656
Molecular subtype
Luminal A Reference
Luminal B 4.00 (0.81–19.82) .090
Luminal Her 4.50 (0.39–51.3) .226
Her enriched 1.50 (0.29–7.81) .630
Basal-like 3.00 (0.44–20.44) .262
Ki-67/Mib-1>20 1.69 (0.64–4.48) .290
Comedo-like necrosis 2.17 (1.35–3.49) <.05 1.05 (0.99–1.11) .127 .127
Multi-focality/-centricity 4.60 (2.80–7.56) <.05 1.21 (1.14–1.3) <.05 <.05
PVI 6.84 (1.36–34.46) <.05 1.27 (0.97–1.64) .080 .095
Peritumoral inflammation 5223752.96 (0–Inf) .977
Tumor grading ≥2 3.43 (1.35–8.71) <.05 1.08 (1.00–1.15) <.05 .066
ITC 6.84 (1.36–34.46) <.05 1.35 (1.04–1.75) <.05 <.05
Nodal status>N0 2.98 (1.11–8.00) <.05
LN micrometastases 3.85 (1.26–11.8) <.05 1.24 (1.05–1.48) <.05 <.05
LN macrometastases 1.33 (0.15–11.52) .797
BMI=body mass index, ITC= isolated tumor cells, LN= lymph node, PVI=peritumoral vascular invasion.
(x) Multivariate model, (
∗
) Benjamini and Hochberg correction.
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model with non surgical therapy adjustment (adjuvant chemo-
therapy, adjuvant radiotherapy, and adjuvant hormonal thera-
py), as in Table 4B, DFS was significantly influenced by DCISM,
clinical suspicion of a palpable lesion, and tumor grading ≥2.
We also assessed the role of lymph node (LN) metastases in
DCISM. DCISM without LN metastasis had a 5 year OS of
99.83% (95% CI 99.49%–100%) while DCISM with LN
metastasis had a 5 year OS of 85.71% (95% CI 63.34%–100%)
(P<.05).3.4. Predictive factors
Table 5 presents the predictive factors for microinvasion among
DCIS. The following were found to be significantly associated
with an increased occurrence of microinvasion: tumor multi-
focality/multicentricity, ITCs, and nodal micrometastases. In the
multivariate model, also even tumor grading ≥2, PVI, and
comedo-like necrosis were found to be significantly predictive.
The area below the curve of the multivariate model was 72.5%
(95%CI: 66.7%–78.3%).
The predictive factors for nodal metastases among DCIS
patients were also investigated, and only postmenopausal status
was found to be a protective factor (OR 0.96 95% CI 0.93–0.99
P<.05) and DCISM to be a risk factor (OR 1.04 95% CI 1.00–
1.09 P<.05). Furthermore, we tested the predictive factors for
ITCs and found only older age to be a protective factor (OR 0.99
95% CI 0.90–1.00 P<.05) and DCISM to be a risk factor (OR
1.03 95% CI 1.01–1.05 P<.05).4. Discussion
In this study, we reviewed our experience with SLNB in patients
affected by DCIS and DCISM and compared their clinical6outcome with IDC sized up to pT1. Nodal micrometastases
resulted 6.0% in DCISM and 1.7% in DCIS while macro-
metastases were 3.6% in DCISM and 0.9% in DCIS. OS andDFS
of DCISM resulted similar to IDC and shorter than DCIS.
Significant predictors for OS or DFS, apart frommicroinvasion in
DCIS, were also: IDC, tumor grading ≥2, nodal macrometa-
stases, peritumoral inflammation, basal-like subtype, tumor
multifocality/multicentricity, comedo-like necrosis, clinical
suspicion of a palpable lesion, and Mib1 >20%. In the
multivariate model, among DCIS, resulting predictive factors
for microinvasion are: comedo-like necrosis, tumor multifocality/
multicentricity, PVI, tumor grading ≥2, ITCs, and nodal
micrometastases.
Since the introduction of a mammographic screening in our
region, the prevalence of DCIS has increased, thanks to better
microcalcifications detection.[21,22] The current literature advises
SLNB for DCIS only in the case of very large DCIS with
microinvasion suspicion and mastectomy, as the procedure will
no longer be reliable.[23–27]
Regarding population characteristics, invasive carcinomas
resulted clinically palpable in more than half the patients with
DCIS with and without microinvasion. This may be a good
indicator of the efficacy of mammographic screening, which is
very sensitive for microcalcifications and consequently very
accurate in early DCIS detection.
Other interesting data emerge for what concerns breast
surgery. In fact, the mastectomy rate resulted surely higher in
cases of DCIS and DCISM than IDC within 2cm of size. In fact,
DCIS is frequently multifocal or multicentric and, despite its low
aggressivity, can more frequently require complete breast
demolition.
While taking into account tumor characteristics, DCISM
resulted in a higher prevalence of less favorable prognostic
factors, including basal-like subtype (available only in a minority
Bertozzi et al. Medicine (2019) 98:1 www.md-journal.comof DCIS or DCISM, due to missing data), high nuclear grading,
high proliferation index, comedo-like necrosis, multifocality/
multicentricity, and bunched axillary nodes. Most probably also
due to these unfavorable characteristics, DCISM OS and DFS
resulted more similar to those of IDC than of pure DCIS, which
has a very favorable prognosis. However, in the literature, there is
still disagreement about the impact of microinvasion on patient
prognosis, without any differences between DCISM and DCIS in
certain instances.[28–30] Our results confirmed previous studies
that showed a reduced OS in DCISM than DCIS.[28,29] In
addition, several studies suggested that DCISM survival out-
comes were intermediate between DCIS and IDC, while in our
study we found it to be very similar to IDC, mainly because of
distant metastases occurrence.[30,31]
In the literature, the incidence of positive sentinel nodes in case
of DCIS varies between 1.4% and 13%.[32,33] In our population,
the prevalence of positive sentinel nodes in cases of DCIS resulted
2.6%. Usually, in these particular cases, surgical specimen was
reviewed in order to detect eventual occult microinvasive foci,
which in some cases were not found. Some authors described an
upstage of DCIS to IDC after definitive surgery of 16.6%, and to
microinvasive carcinoma of 16.6%, with a global underestima-
tion rate of invasive disease of even 33%.[34] Therefore, any case
of a positive sentinel node in the absence of evident microinvasive
foci should be treated as a sort of cancer of unknown primary
(CUP) syndrome, and thus therapies have been administered as in
cases of IDC.[35] In addition, as emerged from our study, 5 year
OS of DCISM with LN metastases was significantly lower than
that of DCISM without LN metastases.
Taking into consideration predictive factors for microinvasion
in cases of DCIS, in the literature it is associated with comedo-like
necrosis, hormone receptor negativity, extensive DCIS or high
grading.[28,36] Moreover, some radiological aspects may predict
microinvasion by DCIS, including microcalcifications and high-
degree of vascularization.[37] Among predictive factors for
microinvasion in our population, comedo-like necrosis and
PVI may represent an advanced evolutive stage of DCIS,
multifocality/multicentricity may correlate with larger lesions,
tumor grading ≥2, ITCs or nodal micrometastases may be
associated with amore aggressive biological behavior.Moreover,
this data suggests the importance of recognizing ITCs and
micrometastases in cases of DCIS, as they may be a sign of
misdiagnosed microinvasion foci. In fact, it is probably easier to
find ITCs in an SLNB than a microinvasion focus in an extended
DCIS. Among articles studying the predictive factors for
microinvasion in DCIS, postoperative upstaging was mostly
correlated with younger age, palpable mass, mammographic or
ultrasonographic mass, core-needle biopsy, microinvasion suspi-
cion at biopsy, large DCIS, high grading, comedo-like necrosis,
hormonal receptors negativity, Her2/neu overexpression, and
periductal inflammation.[36,38–42] In addition, Wang et al and
Sakr et al agree with our results that a positive SLNB may be
predictive of microinvasion and allow a prompt upstaging of
DCIS when required.[29,43]
For what concerns nodal metastases in cases of DCIS, there are
still many controversies. In particular, some authors found that
an associated intraductal component of carcinoma >2cm in size
is a specific risk factor for ITCs and nodal metastases in cases of
microinvasive carcinoma.[44] In our study, we found DCISM to
be a risk factor for nodal metastases or ITCs, and older age or
postmenopausal status to be protective factors. On the contrary,
another study excluded the role of the number and extension of
microinvasive foci in the development of nodal metastases.[45] In7our opinion, these data from the literature and our results support
the hypothesis of a molecular heterogeneity in DCIS,[46] so that a
more aggressive DCIS results more likely to develop nodal
metastases than a milder one. Supplemental Table 3, http://links.
lww.com/MD/C726 shows a review of the current literature on
SLNB in cases of DCISM. Among the 32 studies about SLNB in
DCISM, 37.50% did not show a clear opinion, 43.75% were in
favor of performing SLNB, while only 18.75% were clearly
contrary to SLNB procedure. In particular, the studies with wider
population size were in favor of performing SLNB in DCISM.
Despite the quite low percentage of positive nodes in DCISM in
cases of LN positivity, the survival was significantly reduced in
our study.
Some recent studies pointed out the negative prognostic value
of Her2 in both DCIS and DCISM.[47–49] Unfortunately, this data
may be missing in cases of microinvasion if the focus does not
provide enough material to be immunohistochemically tested. In
fact, in our study, we could not find survival differences in DCIS
or DCISM in respect to Her2 positivity, because it was available
only in a limited number of cases. Moreover, a possible role of
Her2 in predicting in situ local recurrences in DCIS supports the
implementation of routine Her2 testing in patients with any type
of ductal intraepithelial neoplasia.[50]
The main limitations of this study were the retrospective design
and the missing data regarding some biological characteristics of
breast cancer, such as Her2 expression, which was not routinely
assessed in DCIS, and in many cases of DCISM the invasive
component could not be tested because of the paucity of invasive
tissue. On the other hand, its points of strength were the wide
number of considered DCIS and DCISM, the uniform manage-
ment due to regular breast meeting discussions in a single center
experience, and the median follow up of 95 months (interquartile
range (IQR) 61–123) among DCISM and DCIS patients, which
represents one of the longest follow-ups in the current
literature.[29]
In summary, our study suggests that despite its rarity, nodal
metastasis may occur also in cases of DCIS, which in most
cases are micrometastasis. Even in the absence of an evident
invasive component, microinvasion should always be sus-
pected in these cases, and their management should be the
same as for IDC. In our opinion, ITCs in association with
nodal micrometastases could be a useful marker for DCISM,
and ITCs should be considered in future studies for DCISM
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